EFFICACY AND SAFETY OF ERAXIS™/ECALTA® (ANIDULAFUNGIN) COMPARED TO CANCIDAS® (CASPOFUNGIN) IN NEUTROPENIC PATIENTSWITH INVASIVE CANDIDA INFECTION

Mise à jour : Il y a 5 ans
Référence : EUCTR2008-005277-35

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

•To assess the efficacy of anidulafungin and caspofungin with respect to the overall global response (clinical and microbiological success) at the EOIVT in neutropenic subjects with a confirmed diagnosis of invasive infection due to Candida sp.


Critère d'inclusion

  • INVASIVE CANDIDIA INFECTIONS